Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing a pill to treat sickle cell disease

4 Jul 2024

Abstract excerpt

A newly identified epigenetic modifier increases fetal hemoglobin in preclinical studies.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to Prenatal Screening and Diagnostics

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38963861
DOI: 10.1126/science.adq3757

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing a pill to treat sickle cell diseasePMID 38963861Read ↗

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell diseaseSemantic proximity Read ↗

Recent Advances in the Treatment of Sickle Cell DiseaseSemantic proximity Read ↗

Exploring epigenetic and microRNA approaches for γ-globin gene regulationSemantic proximity Read ↗

Elevating fetal hemoglobin: recently discovered regulators and mechanismsSemantic proximity Read ↗

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseSemantic proximity Read ↗

Dissecting the epigenetic regulation of the fetal hemoglobin genes to unravel a novel therapeutic approach for β-hemoglobinopathiesSemantic proximity Read ↗

Concise Review: Epigenetic Regulation of Hematopoiesis: Biological Insights and Therapeutic ApplicationsSemantic proximity Read ↗

MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell diseaseSemantic proximity Read ↗

Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic TargetsSemantic proximity Read ↗

Prenatal Somatic Cell Gene Therapies: Charting a Path Toward Clinical Applications (Proceedings of the CERSI‐FDA Meeting)Semantic proximity Read ↗

Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesisSemantic proximity Read ↗

Genomic discovery and functional validation of MRP1 as a novel fetal hemoglobin modulator and potential therapeutic target in sickle cell diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.